Quick Answer: These are two drugs, not three. Ozempic and Wegovy both contain semaglutide — the difference is maximum dose and registered use. Mounjaro contains tirzepatide, which acts on two hormone receptors instead of one and produces the greatest average weight loss of the three. All are prescription-only in Malaysia under the Poisons Act 1952.
The Key Thing Most Comparisons Miss
You’re comparing three brand names, but only two active ingredients:
| Brand | Active ingredient | Registered for |
|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes |
| Wegovy | Semaglutide | Chronic weight management |
| Mounjaro | Tirzepatide | Type 2 diabetes |
Ozempic and Wegovy are the same drug. Same molecule, same manufacturer, different maximum dose and different label.
The genuine pharmacological difference in this comparison is Mounjaro versus the other two — because tirzepatide works differently from semaglutide at a mechanistic level.
Quick Comparison
| Mounjaro | Ozempic | Wegovy | |
|---|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide | Semaglutide |
| Mechanism | GLP-1 + GIP | GLP-1 only | GLP-1 only |
| Registered for | Type 2 diabetes | Type 2 diabetes | Weight management |
| Frequency | Weekly injection | Weekly injection | Weekly injection |
| Maximum dose | 15 mg | 2.0 mg | 2.4 mg |
| Average weight loss | 20%+ | 10–15% | ~15% |
| Manufacturer | Eli Lilly | Novo Nordisk | Novo Nordisk |
What Makes Mounjaro Different?
This is the most clinically significant point in the comparison.
Ozempic and Wegovy act on one receptor: GLP-1. They mimic glucagon-like peptide-1, a gut hormone that regulates appetite, slows gastric emptying, and supports glucose-dependent insulin release.
Mounjaro acts on two. Tirzepatide is a dual GLP-1 and GIP receptor agonist. GIP — glucose-dependent insulinotropic polypeptide — is a second gut hormone involved in insulin response and fat metabolism.
Targeting both pathways produces greater average weight reduction than semaglutide in head-to-head trials. This is the actual reason Mounjaro outperforms on average, and it’s a genuine pharmacological difference rather than a marketing claim.
The important caveat: better on average doesn’t mean better for you. Tolerability varies considerably between individuals, and some people respond better to semaglutide or tolerate it more comfortably. Cost and availability also differ.
Mounjaro vs Ozempic
| Mounjaro | Ozempic | |
|---|---|---|
| Ingredient | Tirzepatide | Semaglutide |
| Mechanism | GLP-1 + GIP | GLP-1 |
| Weight loss | 20%+ | 10–15% |
| Registered for | Type 2 diabetes | Type 2 diabetes |
Both are weekly injections, both registered for type 2 diabetes, and both frequently prescribed off-label for weight management based on clinical assessment.
Mounjaro generally produces more weight loss. The trade-offs are cost — it typically prices higher — and availability, which has fluctuated since launch.
Side effect profiles are broadly similar, since both are gut-hormone medications. Gastrointestinal effects dominate for both.
Mounjaro vs Wegovy
| Mounjaro | Wegovy | |
|---|---|---|
| Ingredient | Tirzepatide | Semaglutide |
| Mechanism | GLP-1 + GIP | GLP-1 |
| Weight loss | 20%+ | ~15% |
| Registered for | Type 2 diabetes | Weight management |
This is the more meaningful comparison if weight loss is your goal, since Wegovy is the semaglutide formulation actually developed for it.
Mounjaro shows greater average weight reduction. Wegovy holds the registration advantage — it’s specifically licensed for chronic weight management, whereas using Mounjaro for weight loss is off-label.
For some patients that distinction matters; for others it doesn’t, since off-label prescribing is lawful, common, and based on clinical judgement.
Ozempic vs Wegovy
Same molecule. The differences are narrow.
| Ozempic | Wegovy | |
|---|---|---|
| Maximum dose | 2.0 mg weekly | 2.4 mg weekly |
| Registered for | Type 2 diabetes | Weight management |
| Weight loss | 10–15% | ~15% |
Wegovy reaches a marginally higher dose and its clinical trials were designed around weight outcomes rather than glycaemic control.
In practice, which one you’re offered often comes down to availability rather than clinical preference. The drug is identical.
Which Produces the Most Weight Loss?
Based on clinical trial averages:
- Mounjaro (tirzepatide) — above 20%
- Wegovy (semaglutide 2.4mg) — around 15%
- Ozempic (semaglutide 2.0mg) — 10–15%
Three caveats worth taking seriously:
These are averages. Individual results vary substantially. Some people lose considerably more on semaglutide than the average tirzepatide patient.
Trial conditions aren’t real life. Participants receive structured dietary and activity support alongside medication. Results without that support are typically lower.
Adherence beats potency. A medication you tolerate and continue outperforms a stronger one you abandon after six weeks because of nausea.
Which Is Right for You?
| Your situation | Likely consideration |
|---|---|
| Type 2 diabetes | Ozempic or Mounjaro — both registered for this |
| Weight management, registered indication matters | Wegovy |
| Weight management, maximum effect | Mounjaro, where available |
| Previously struggled with GLP-1 side effects | Discuss slower titration, or a different molecule |
| Cost is a primary constraint | Discuss — pricing differs meaningfully between them |
The honest position: this isn’t a choice made from a comparison table. Your doctor will weigh your medical history, contraindications, current medications, what’s actually available, and what you can realistically sustain — since these are ongoing rather than one-off treatments.
Are They Available in Malaysia?
Ozempic is registered with Malaysia’s NPRA for type 2 diabetes and is established here.
Wegovy and Mounjaro — registration and availability status should be verified directly with NPRA or your prescribing doctor, as this changes over time and sources conflict. You can check any product through the NPRA Quest3+ registration database.
All Three Are Prescription-Only
GLP-1 receptor agonists in Malaysia — including semaglutide and tirzepatide — are classified as Group B Poisons under the Poisons Act 1952.
They may legally be supplied only by a registered medical practitioner treating their own patient, or by a registered pharmacist against a valid prescription.
Supplying them outside these conditions is a criminal offence. Importing personally from overseas without an NPRA permit risks customs seizure under the Sale of Drugs Act 1952.
Verifying Authentic Product
Counterfeit semaglutide has been seized in Malaysia, and the WHO issued a global alert in June 2024 on falsified semaglutide — one batch contained insulin glargine instead, which could cause dangerous hypoglycaemia in a non-diabetic patient.
Before accepting any product:
- MAL registration number on the packaging
- Meditag or FarmaTag hologram on the box
- Cold chain intact — the pen should be refrigerated on handover
- Never buy from marketplaces, social media, or messaging apps
Side Effects: How Do They Compare?
Broadly similar across all three, since all are gut-hormone medications.
Common:
- Nausea (most frequent)
- Vomiting, diarrhoea, constipation
- Abdominal pain, reduced appetite
- Fatigue, headache
- Injection site reactions
Serious but uncommon:
- Pancreatitis
- Gallbladder problems, more likely with rapid weight loss
- Kidney issues, usually secondary to dehydration
- Thyroid C-cell tumours observed in rodent studies
Contraindicated for all three if you have a personal or family history of medullary thyroid carcinoma (MTC), MEN 2 syndrome, or are pregnant, breastfeeding, or planning pregnancy.
Titration Matters More Than Which Drug
All three start at a deliberately sub-therapeutic dose and increase gradually over weeks. This isn’t bureaucratic caution — escalating too quickly is the main cause of severe nausea, and the most common reason people abandon treatment.
If you’re struggling at a given dose, staying there longer is a legitimate option. Tell your doctor rather than pushing through or stopping on your own.
What Happens If You Stop?
This applies equally to all three.
Appetite returns to baseline and weight regain is common without sustained lifestyle change. These medications manage appetite while you take them; they don’t permanently reset it.
Rapid weight loss on any of them can also cause facial volume loss and loose skin. See our guide on Ozempic face — it’s driven by the speed of loss, not by which drug you’re on.
These work best alongside genuine dietary and activity change, not instead of it. Our guides on losing weight safely and diet planning in Malaysia cover the foundation that determines whether results hold.
Frequently Asked Questions
Are Ozempic and Wegovy the same drug? Yes. Both are semaglutide from Novo Nordisk. Wegovy reaches a higher maximum dose (2.4mg vs 2.0mg) and is registered for weight management rather than diabetes.
Is Mounjaro better than Ozempic? Mounjaro produces greater average weight loss because tirzepatide targets two receptors (GLP-1 and GIP) rather than one. Whether it’s better for you depends on tolerability, cost, availability, and your medical history.
Why does Mounjaro work better? It’s a dual agonist. Semaglutide acts on GLP-1 only; tirzepatide acts on GLP-1 and GIP, a second gut hormone involved in insulin response and fat metabolism.
Which has fewer side effects? All three have broadly similar profiles, dominated by gastrointestinal effects. Individual tolerance varies more than the drugs do.
Can I switch between them? Only under medical supervision. Switching requires dose adjustment and shouldn’t be self-directed.
Are they available in Malaysia? Ozempic is established here. Verify current availability for Wegovy and Mounjaro with your doctor or through NPRA, as this changes.
Can I buy them online? No. All are Group B Poisons requiring a prescription. Online sellers operate illegally and counterfeit product has been seized locally.
Which should I ask my doctor about? Rather than requesting a specific brand, describe your goals and history. Availability, contraindications, and tolerability often matter more than a comparison table.
Bottom Line
Two drugs, three brand names. Ozempic and Wegovy are semaglutide — differing only in dose ceiling and registered use. Mounjaro is tirzepatide, and its dual GLP-1/GIP action is the real distinction, producing the highest average weight loss of the three.
But average results aren’t your results. Tolerability, cost, availability, and whether you can sustain treatment matter at least as much as which molecule is strongest on paper.
None of them works without the rest of the picture. Weight regain after stopping is common, which makes the lifestyle side the part that determines whether any of this lasts.
At CLÉO Clinic, weight management assessments are carried out by LCP-certified doctors who will discuss which options suit your health profile — including when medication isn’t the right starting point. See our treatable conditions, or book a consultation.
